Glaxosmithkline | Passività Correnti



Current Liabilities Cambiamento Data
AbbVie USD 38.75B 4.31B 2024-12
Amgen USD 23.1B 2.79B 2024-12
AstraZeneca USD 29.13B 1.26B 2025-03
Aurora Cannabis CAD 149.81M 40.71M 2024-12
Bausch Health Companies USD 4.26B 2.5B 2025-03
Bristol-Myers Squibb USD 24.07B 296M 2025-03
Canopy Growth CAD 97.02M 184.27M 2024-12
Corcept Therapeutics USD 140.77M 14.56M 2024-12
Drreddys Laboratories INR 131.95B 2.65B 2024-12
Eli Lilly USD 30.07B 1.69B 2025-03
GlaxoSmithKline GBP 20.83B 866M 2025-03
Glaxosmithkline GBP 21.7B 238M 2024-12
Indivior 1.01B 66M 2025-03
J&J USD 56.9B 6.58B 2025-03
Merck USD 28.42B 1.17B 2024-12
Novartis USD 28.69B 560M 2024-12
Pacira USD 309.92M 3.52M 2024-12
Perrigo USD 1.04B 406.3M 2024-12
Pfizer USD 43B 216M 2024-12
Prestige Brands USD 102.54M 4.36M 2024-12
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 32.22B 3.06B 2025-03
Supernus Pharmaceuticals USD 292.4M 889K 2024-12
Takeda JPY 2.1T 289.27B 2024-12
Teva Pharmaceutical Industries USD 12.8B 1B 2024-12
Zoetis USD 3.41B 1.71B 2024-12



Glaxosmithkline Passività Correnti - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - May 2025.